VolitionRx (NYSE:VNRX) Now Covered by StockNews.com

Equities research analysts at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a report released on Wednesday. The firm set a “sell” rating on the stock.

Separately, Benchmark reiterated a “hold” rating on shares of VolitionRx in a report on Friday, August 16th.

VolitionRx Trading Up 4.0 %

Shares of VNRX stock opened at $0.69 on Wednesday. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.23. The stock has a fifty day simple moving average of $0.68 and a two-hundred day simple moving average of $0.68. The stock has a market capitalization of $63.94 million, a price-to-earnings ratio of -1.92 and a beta of 1.10.

Institutional Trading of VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Geode Capital Management LLC increased its stake in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 730,448 shares of the company’s stock after purchasing an additional 95,900 shares during the quarter. Geode Capital Management LLC owned approximately 0.79% of VolitionRx worth $439,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.